1. Home
  2. ICU vs NXL Comparison

ICU vs NXL Comparison

Compare ICU & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SeaStar Medical Holding Corporation

ICU

SeaStar Medical Holding Corporation

HOLD

Current Price

$3.06

Market Cap

9.1M

Sector

Health Care

ML Signal

HOLD

Logo Nexalin Technology Inc.

NXL

Nexalin Technology Inc.

HOLD

Current Price

$0.39

Market Cap

10.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICU
NXL
Founded
2018
2010
Country
United States
United States
Employees
N/A
8
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.1M
10.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ICU
NXL
Price
$3.06
$0.39
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
82.2K
810.7K
Earning Date
05-14-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$53.00
$15.52
Revenue Next Year
$50.00
$100.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.22
$0.31
52 Week High
$5.10
$2.00

Technical Indicators

Market Signals
Indicator
ICU
NXL
Relative Strength Index (RSI) 42.02 40.14
Support Level $2.26 $0.35
Resistance Level $4.96 $0.48
Average True Range (ATR) 0.28 0.06
MACD 0.00 -0.02
Stochastic Oscillator 41.46 6.78

Price Performance

Historical Comparison
ICU
NXL

About ICU SeaStar Medical Holding Corporation

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.

About NXL Nexalin Technology Inc.

Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Share on Social Networks: